What is the role of dapagliflozin in acute decompensated heart failure?

Role of Dapagliflozin in Acute Decompensated Heart Failure

Dapagliflozin should be initiated during hospitalization for acute decompensated heart failure (ADHF) once patients are clinically stabilized, as it reduces cardiovascular mortality and worsening heart failure events while safely optimizing guideline-directed medical therapy. 1, 2, 3

Evidence-Based Recommendation

The 2022 ACC/AHA/HFSA guidelines establish SGLT2 inhibitors as foundational therapy for heart failure across the ejection fraction spectrum 1. While the landmark DAPA-HF and DELIVER trials enrolled predominantly stable outpatients, emerging evidence specifically addresses in-hospital initiation during ADHF.

Timing of Initiation

Start dapagliflozin 10 mg once daily when patients meet stabilization criteria:

• Systolic blood pressure >100 mmHg maintained for 6+ hours
• No increase in IV loop diuretics for 6 hours
• No IV vasodilators for 6 hours
• No IV inotropes for 24 hours
• eGFR ≥30 mL/min/1.73 m² 4, 3

This typically occurs on hospital day 2-7 of admission 3, 5.

Clinical Benefits in ADHF

The DAPA ACT HF-TIMI 68 trial (n=2,401) showed that while in-hospital dapagliflozin initiation did not significantly reduce the primary endpoint of CV death or worsening HF at 60 days (HR 0.86,95% CI 0.68-1.08, p=0.20), the meta-analysis of all hospitalized HF trials demonstrated significant benefit: 31% reduction in CV death or worsening HF (HR 0.71,95% CI 0.54-0.93, p=0.012) and 43% reduction in all-cause mortality (HR 0.57,95% CI 0.41-0.80, p=0.001) 3.

The DICTATE-AHF trial (n=240) demonstrated that early dapagliflozin initiation:

• Reduced total loop diuretic requirements (560 mg vs 800 mg furosemide equivalent, p=0.006)
• Decreased need for IV diuretic up-titrations
• Enhanced 24-hour natriuresis (p=0.03) and urine output (p=0.005)
• Expedited hospital discharge 5

Diuretic Synergy

Dapagliflozin enhances diuresis without increasing diuretic doses. It works synergistically with loop diuretics by blocking sodium reabsorption in the proximal tubule, while loop diuretics act on the loop of Henle. This dual mechanism achieves equivalent decongestion with lower diuretic doses, potentially reducing diuretic resistance 5.

Safety Profile in ADHF

Dapagliflozin demonstrates excellent safety during acute hospitalization:

• No increase in worsening renal function (5.9% vs 4.7% placebo) 3
• Symptomatic hypotension rates remain low (3.6% vs 2.2%) 3
• No increase in diabetic ketoacidosis, hypovolemia, or acute kidney injury 5, 6
• Safe across eGFR range down to 30 mL/min/1.73 m² 7

Efficacy Across Clinical Spectrum

The treatment effect is consistent regardless of:

• LVEF (works across HFrEF, HFmrEF, and HFpEF) 2
• Diabetes status 1, 2
• Baseline eGFR (down to 30 mL/min/1.73 m²) 7
• Severity of HF (including NYHA class III/IV) 8

Mortality and Morbidity Impact

FDA-approved data from DAPA-HF and DELIVER trials show:

• 26% reduction in composite CV death/HF hospitalization/urgent HF visits (HR 0.74, p<0.0001 in HFrEF; HR 0.82, p=0.0008 in HFpEF) 2
• 30% reduction in HF hospitalizations 1, 2
• 18% reduction in CV death in DAPA-HF 1
• Benefits emerge early and continue to diverge over time 2

Practical Implementation Algorithm

Step 1: Assess eligibility during ADHF hospitalization

• eGFR ≥30 mL/min/1.73 m²
• SBP >100 mmHg stable for 6+ hours
• No active IV vasopressors/inotropes

Step 2: Initiate dapagliflozin 10 mg once daily when stabilized (typically day 2-7)

Step 3: Continue standard diuretic protocol but anticipate:

• Enhanced diuresis within 24 hours
• Potential to reduce loop diuretic doses
• Faster achievement of euvolemia

Step 4: Monitor for (rare) adverse effects:

• Genital mycotic infections (most common)
• Volume depletion (adjust diuretics as needed)
• Euglycemic DKA (extremely rare, hold if patient NPO for procedures)

Critical Caveats

Contraindications:

• eGFR <30 mL/min/1.73 m² (insufficient efficacy)
• Type 1 diabetes (DKA risk)
• SBP <95-100 mmHg 1
• Active ketoacidosis

Temporary holds: Consider holding during acute illness with prolonged NPO status, severe dehydration, or diarrhea causing volume depletion 1.

Metabolic Mechanisms

Recent data suggest dapagliflozin improves myocardial energetics by shifting substrate utilization from fatty acids to more efficient ketone metabolism, reducing circulating free fatty acids and β-hydroxybutyrate levels, which correlate with improved LVEF and reverse remodeling 9. This addresses the "myocardial metabolic starvation" hypothesis in heart failure.

Bottom Line

Initiate dapagliflozin during ADHF hospitalization once clinically stable—it simultaneously achieves decongestion and optimizes GDMT, reducing both short-term and long-term cardiovascular events and mortality. The drug is safe, well-tolerated, and effective across all HF phenotypes, making it a cornerstone of modern ADHF management 1, 3, 5, 6.